DUBLIN–(BUSINESS WIRE)–The “Thalassemia Pipeline Research Monitor, 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook” report has been added to ResearchAndMarkets.com’s offering.

PIPELINE HIGHLIGHTS

Thalassemia is one of the widely researched conditions during 2020 with 37 companies actively focusing on realizing pipeline’s potential. Development of Thalassemia medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Thalassemia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Thalassemia.

Good progress is anticipated during 2020 and 2021 with Thalassemia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Thalassemia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

DRUG DEVELOPMENT PIPELINE OVERVIEW

The Thalassemia pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Thalassemia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Thalassemia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Thalassemia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report. (Read more…)

DRUG PROFILES

Thalassemia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Thalassemia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Thalassemia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 37 Thalassemia companies including company overview, key snapshot, contact information, and their strategies on accelerating Thalassemia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Reasons to Buy

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Thalassemia
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Companies Mentioned

• Acceleron Pharma Inc
• Agios Pharmaceuticals Inc
• Allife Medical Science and Technology Co Ltd
• Aruvant Sciences
• ASC Therapeutics Inc
• Beam Therapeutics Inc
• bluebird bio Inc
• Cetya Therapeutics Inc
• CSL Behring
• Disc Medicine Inc
• EdiGene Inc
• Editas Medicine Inc
• EmeraMed Ltd
• Errant Gene Therapeutics LLC
• ExCellThera Inc
• Fulcrum Therapeutics Inc
• Gamida Cell Ltd
• Gilead Sciences Inc
• Imara Inc
• Invenux LLC
• Ionis Pharmaceuticals Inc
• Kymab Group Ltd
• Merganser Biotech Inc
• Nanomedic Inc
• Orchard Therapeutics Ltd
• Phoenicia Biosciences Inc
• Protagonist Therapeutics Inc
• Rare Partners Srl
• Regenacy Pharmaceuticals LLC
• Sangamo Therapeutics Inc
• Sanquin Plasma Products BV
• Shanghai Bioray Laboratory Inc
• Silence Therapeutics Plc
• Syros Pharmaceuticals Inc
• Trucode Gene Repair Inc
• Vertex Pharmaceuticals Inc
• Vifor Pharma AG

For more information about this report visit https://www.researchandmarkets.com/r/nwrb82

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

DUBLIN–(BUSINESS WIRE)–The “Thalassemia Pipeline Research Monitor, 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook” report has been added to ResearchAndMarkets.com’s offering.

PIPELINE HIGHLIGHTS

Thalassemia is one of the widely researched conditions during 2020 with 37 companies actively focusing on realizing pipeline’s potential. Development of Thalassemia medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Thalassemia market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Thalassemia.

Good progress is anticipated during 2020 and 2021 with Thalassemia pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Thalassemia pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

DRUG DEVELOPMENT PIPELINE OVERVIEW

The Thalassemia pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Thalassemia pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Thalassemia presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Thalassemia pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report. (Read more…)

DRUG PROFILES

Thalassemia development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Thalassemia drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Thalassemia. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 37 Thalassemia companies including company overview, key snapshot, contact information, and their strategies on accelerating Thalassemia pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Reasons to Buy

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Thalassemia
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Companies Mentioned

• Acceleron Pharma Inc
• Agios Pharmaceuticals Inc
• Allife Medical Science and Technology Co Ltd
• Aruvant Sciences
• ASC Therapeutics Inc
• Beam Therapeutics Inc
• bluebird bio Inc
• Cetya Therapeutics Inc
• CSL Behring
• Disc Medicine Inc
• EdiGene Inc
• Editas Medicine Inc
• EmeraMed Ltd
• Errant Gene Therapeutics LLC
• ExCellThera Inc
• Fulcrum Therapeutics Inc
• Gamida Cell Ltd
• Gilead Sciences Inc
• Imara Inc
• Invenux LLC
• Ionis Pharmaceuticals Inc
• Kymab Group Ltd
• Merganser Biotech Inc
• Nanomedic Inc
• Orchard Therapeutics Ltd
• Phoenicia Biosciences Inc
• Protagonist Therapeutics Inc
• Rare Partners Srl
• Regenacy Pharmaceuticals LLC
• Sangamo Therapeutics Inc
• Sanquin Plasma Products BV
• Shanghai Bioray Laboratory Inc
• Silence Therapeutics Plc
• Syros Pharmaceuticals Inc
• Trucode Gene Repair Inc
• Vertex Pharmaceuticals Inc
• Vifor Pharma AG

For more information about this report visit https://www.researchandmarkets.com/r/nwrb82

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900